Giulia Pascolini | Neurodevelopmental Disorders | Best Researcher AwardĀ 

Dr. Giulia Pascolini | Neurodevelopmental Disorders | Best Researcher AwardĀ 

Dermopathic Institute of the Immaculate, IDI-IRCC | ItalyĀ 

Author Profile

ScopusĀ 

Orcid ID

Google Scholar

šŸŒŸ Biography of Giulia Pascolini, MD, PhD

šŸŽ“ EARLY ACADEMIC PURSUITS

Giulia Pascolini's journey in medical science began with a Degree in Medicine from Sapienza University of Rome in 2008, which she completed with honors. Following this, she pursued specialization in Medical Genetics at Tor Vergata University of Rome, graduating with honors in 2015 after five years of in-depth study. Driven by her passion for genetics, Dr. Pascolini went on to earn her Ph.D. in Medical Genetics from Sapienza University in 2019, establishing her expertise in a rapidly advancing field. In 2022, she further expanded her knowledge with a Master of II level in Rare Diseases, also from Sapienza University, solidifying her role as a leading expert in rare genetic disorders.

šŸ©ŗ PROFESSIONAL ENDEAVORS

Dr. Pascolini's professional career is marked by extensive experience across multiple prestigious institutions. Currently, she is a Clinical Geneticist and head of the Clinical Genetics Service at the Istituto Dermopatico dell'Immacolata (IDI-IRCCS) in Rome, Italy. Since September 2023, she also holds a position as Professor of Medical Genetics at the Faculty of Medicine and Surgery at Tor Vergata University of Rome. Over the years, she has held various roles, including serving as a clinical geneticist at Bambino GesĆ¹ Childrenā€™s Hospital and a researcher at San Camillo-Forlanini Hospital. Her long-standing commitment to clinical genetics spans over 15 years, with a focus on intellectual disability syndromes, dysmorphology, and developmental disorders.

šŸ”¬ CONTRIBUTIONS AND RESEARCH FOCUS ON NEURODEVELOPMENTAL DISORDERSĀ 

Dr. Pascolini's research primarily centers around Developmental Disorders of Chromatin Remodeling (DDCRs), intellectual disability (ID) syndromes, and genodermatoses. She has played a crucial role in the study of the skin phenotype in rare genetic diseases, and her work on deep learning technologies for diagnosing genetic syndromes using facial phenotype recognition is groundbreaking. Her involvement with FDNA Inc. and the DeepGestalt technology is a testament to her contributions to advancing medical genetics through innovative platforms. She is also a principal investigator for multiple research projects, including studies on rare cutaneous tumors and familial melanoma, with funding of over ā‚¬47,000 for these projects.

šŸŒ IMPACT AND INFLUENCE

As a Scientific Board Member of the ADNP Syndrome Italian Association and an editorial board member of the Journal of Pediatric Genetics, Dr. Pascolini has made significant contributions to the broader medical community. Her work has helped shape new approaches to the clinical understanding of complex genetic disorders, particularly in rare diseases and neurodevelopmental syndromes. Through her collaborative efforts with international organizations and her academic roles, she continues to influence both current medical practices and future research directions.

šŸ“š ACADEMIC CITES AND PUBLICATIONS

Dr. Pascolini has authored several impactful works, including her involvement in the DeepGestalt technology article on SETD5-associated intellectual disability published in the Journal of Translational Genetics and Genomics. Her contributions to book chapters, such as her writing on Genomic Copy Number Variants (CNVs) and Autism Spectrum Disorder (ASD), have added substantial value to academic literature. Her expertise has also been recognized through invitations to write for special issues in leading journals, enhancing her standing as a key voice in her field.

šŸ… AWARDS AND RECOGNITION

In 2019, Dr. Pascolini was awarded the Franca Dagna Bricarelli Award for her clinical research on genetic mutations associated with the BAF complex. This prestigious award highlights her excellence in medical genetics and clinical research. Her contributions to the field, recognized by peers and institutions alike, reflect her profound impact on the study and treatment of genetic disorders.

šŸŒŸ LEGACY AND FUTURE CONTRIBUTIONS

With her leadership in clinical genetics, active research on rare skin diseases, and innovative work in genetic syndrome diagnostics, Dr. Pascolini is poised to continue shaping the future of medical genetics. Her contributions to understanding the genetic basis of intellectual disabilities and her work on cutting-edge diagnostic technologies ensure her legacy as a pioneering figure in genetics. As she continues her role in both clinical and academic settings, her future contributions will likely further advance the study and treatment of rare genetic conditions, helping countless individuals worldwide.

šŸ“‘NOTABLE PUBLICATIONSĀ 

"The face of Non-photosensitive trichothiodystrophy phenotypic spectrum: A subsequent study on paediatric population"Ā 

  • Authors: Pascolini, G. , Lipari, M. , Gaudioso, F. , Di Zenzo, G. , Didona, B.
  • Journal: Molecular Genetics and Genomic Medicine
  • Year: 2024

"Usmani-Riazuddin syndrome can have a recognizable phenotype: Report of a novel AP1G1 variant"Ā 

  • Authors: Gnazzo, M. , Pascolini, G. , Parlapiano, G. , Novelli, A. , Baban, A.
  • Journal: Clinical Genetics
  • Year: 2024

"Extended phenotypic characterization of a novel Helsmoortel-van der Aa syndrome case series"Ā 

  • Authors: Pascolini, G., Di Zenzo, G., Panebianco, A., Didona, B., Gozes, I.
  • Journal: American Journal of Medical Genetics
  • Year: 2024

"Ectoderm-derived findings in AymĆØ-Gripp syndrome"Ā 

  • Authors: Pascolini, G., Di Zenzo, G., Morani, P., Didona, B., Panebianco, A.
  • Journal: Journal of Dermatology
  • Year: 2024

"Defining the clinical spectrum of ichthyosis follicularis, atrichia and photophobia clinical association type 1 (IFAP1)"Ā 

  • Authors: Pascolini, G., Fortugno, P., Chandramouli, B., Didona, B., Castiglia, D.
  • Journal: European Journal of Dermatology
  • Year: 2023

Paritha Arumugam | Gene Therapy | Best Researcher Award

Dr. Paritha Arumugam | Gene Therapy | Best Researcher Award

Cincinnati Children's Hospital Medical Center | United States

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Paritha Arumugam's academic journey began at the University of Madras, Bharathi Women's College, where she earned her B.Sc. in Biochemistry in 1991. She continued her education at the University of Madras, Guindy Campus, obtaining her M.Sc. in Biochemistry in 1993, M.Phil. in Biochemistry in 1994, and Ph.D. in Biochemistry in 1998 under the mentorship of Shyamala Devi, C.S. Her academic excellence was recognized with numerous awards, including the Gold Medal for securing the first rank in her M.Sc. program and various other prestigious prizes from the University of Madras.

PROFESSIONAL ENDEAVORS

Dr. Arumugam's professional career is marked by significant roles in both academic and research settings. She served as a Postdoctoral Research Fellow at the Childrenā€™s Hospital Los Angeles (CHLA) from 2004 to 2006, under the guidance of Dr. Punam Malik in the Division of Hematology-Oncology. She later earned an M.S. in Drug Development from the University of Cincinnati in 2011, where she was advised by Kevin L. Skare.Ā Her academic appointments at the University of Cincinnati College of Medicine and Cincinnati Childrenā€™s Hospital Medical Center (CCHMC) have been pivotal. She progressed from Research Instructor in Pediatrics (2015-2019) to her current position as an Assistant Professor in Pediatrics at the Translational Pulmonary Science Center, Division of Pulmonary Biology, beginning in October 2019.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE THERAPY

Dr. Arumugam's research has significantly advanced the fields of biochemistry and molecular biology, with a particular focus on translational pulmonary science. Her work on developing a novel cell transplantation therapy, specifically Pulmonary Macrophage Transplantation, earned her a plenary talk at the NHLBI Celebration of 15 Years of Basic and Translational Progenitor Cell Research in 2023. Her research has garnered numerous awards, including the Excellence in Hemoglobinopathy Research Award from the National Institutes of Health and multiple abstract and travel awards from the American Society of Hematology.

IMPACT AND INFLUENCE

Dr. Arumugam's impact extends beyond her direct research contributions. Her role in advancing clinical practices is underscored by her licensing and certification in Good Clinical Practice for clinical trials involving drugs and devices. Her expertise in conducting investigator-initiated studies according to FDA regulations and GCP has positioned her as a leader in the field, capable of managing investigational agents and overseeing the ethical conduct of clinical trials.

ACADEMIC CITES

Dr. Arumugam's academic excellence has been recognized with several citations and awards throughout her career. Notably, she has been a recipient of the Cincinnati Childrenā€™s Innovation Excellence Award in 2023 and the NHLBI Celebration of 15 Years of Basic and Translational Progenitor Cell Research Poster Award. Her scholarly contributions are also highlighted by her selection as a Translational Sickle Scholar by the National Institutes of Health.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Arumugam's legacy is defined by her dedication to advancing medical science and improving clinical practices. Her pioneering research on pulmonary macrophage transplantation and her contributions to hemoglobinopathy research underscore her commitment to translational science. Looking forward, Dr. Arumugam aims to continue her impactful research, mentor the next generation of scientists, and contribute to significant advancements in pediatric pulmonary biology and therapeutic developments.

NOTABLE PUBLICATIONS